EXCLUSIVE: Versarien – even management or the auditors no longer believe a substantial growth in Graphene sales is credible in the near future
Drug development & clinical trial services company Venn Life Sciences (VENN) has announced audited 2018 results, a placing and acquisition (in which Tom Winnifrith has shares) progress which has seen the shares restored to trading – and we have chatted with CEO Cathal Friel…
Venn Life Sciences (VENN) has served up 2018 results which, predictably, were a bit of a kitchen sink affair. But that is not the real news. This is the RTO of Open Orphan, which will be transformational. Ahead of that the shares will be suspended...
Venn Life Sciences (VENN), the AIM-listed integrated drug development partner, has announced that Raglan Capital, the vehicle of Cathal Friel, has subscribed for loan notes of £250,000...
A tip last month on HotStockRockets - the shares are already comfortably ahead on the tip price, but there looks much more to come...
Search ShareProphets |
Recent Comments |